Proteome Sciences plc(PMSNF)
USD --+0.00%
Reward25Low
Risk67Medium-High
📊75%Data
Thin -74% profit margin · Revenue down 16% YoY
PMSNF
+0.0 · +0.00%
USD · PINK
Proteome Sciences plc | Healthcare
Earnings Deterioration
Market Cap:8.77M
ℹ️
Reward Rating
25
Low
Bottom 1% (model universe)
75% data coverage
ℹ️
Risk Rating
67
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on PMSNF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Proteome Sciences plc?

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally.

PMSNF · Verdict

Limited reward · elevated risk

PMSNF's standout is volatility; balance sheet and profitability weigh on the picture.

Based on 88% data coverage

PMSNF · Verdict

What’s working & what to watch

Strengths 1

  • Volatility95/100

    Top decile vs peers

Watchouts 5

  • Balance sheet6/100

    Current ratio 0.18

  • Profitability9/100

    -70% net margin · 0% ROE

  • Growth13/100

    Revenue -94.0% CAGR

  • Cash flow16/100

    -21% free-cash-flow margin

  • Valuation34/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Proteome Sciences plc?

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 8.77M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (25)

The scoring profile indicates weak reward characteristics across most factors, including momentum and size. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap8.77M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.08
52 Week Low0.01
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding351M
No. of Employees36
IndustryDiagnostics & Research
ExchangePINK
Beta0.24
CurrencyUSD · Reports in GBP